Plague vaccine intranasal - ID Biomedical/USAMRMC

Drug Profile

Plague vaccine intranasal - ID Biomedical/USAMRMC

Alternative Names: Yersinia pestis vaccine intranasal - ID Biomedical/USAMRMC

Latest Information Update: 27 Jun 2007

Price : $50

At a glance

  • Originator ID Biomedical Corporation; United States Army Medical Research and Materiel Command
  • Class Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pneumonic plague

Most Recent Events

  • 27 Jun 2007 Discontinued - Preclinical for Pneumonic plague in USA (Intranasal)
  • 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
  • 23 Sep 2004 ID Biomedical was awarded up to US$8 million from the US NIH to develop a nasally delivered plague vaccine based upon the ID Biomedical's Proteosome™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top